Cancer Research and Treatment

Review Article

The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?: Mariona Riudavets, David Planchard; Cancer Res Treat. 2025;57(2):293-311. Published online November 28, 2024; DOI: https://doi.org/10.4143/crt.2024.714

Antibody drug conjugates (ADCs) are a novel class of therapeutics that structurally are composed by an antibody directed to a tumor epitope connected via a linker to a cytotoxic payload, and that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the pharmacology and design of ADCs, as well as we describe the results of different studies evaluating ADCs in lung cancer directed to several targets including HER2, HER3, TROP2, MET, CEACAM5 and DLL3.

Citations

Citations to this article as recorded by

Evaluating the efficacy and safety of antibody–drug conjugates in non-small cell lung cancer: a systematic review and meta-analysis
Linling Zhang, Hongyuan Jia, Bin Niu
BMC Cancer.2026;[Epub] CrossRef
The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors
Yi-Chen Zhang, Wei-Chi Luo, Jia-Ting Li, Lv Wu, Zhi-Hong Chen, Qing Zhou
Journal of Controlled Release.2026; 393: 114747. CrossRef

11,737 View
445 Download
3 Web of Science
2 Crossref

First
Prev
Page of 1
Next
Last

Search